Using mRNA to enhance immune responses to vaccines for cancer and infectious diseases.
mRNA encoding of immune receptor-targeting antibodies for the augmentation of vaccine-elicited cellular immunity.
['FUNDING_R21'] · UNIVERSITY OF COLORADO DENVER · NIH-10662571
This study is exploring a new way to make vaccines work better by using mRNA to deliver special antibodies that help your immune system fight off cancers and long-lasting infections, so patients might get stronger protection from diseases in the future.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-10662571 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to improve vaccine efficacy by using mRNA to deliver antibodies that target immune receptors. The goal is to enhance cellular immunity, which is crucial for fighting off cancers and chronic infectious diseases. By leveraging successful mRNA vaccine technology, the study aims to simplify the delivery of a combined vaccine adjuvant that has shown promise in generating strong immune responses. Patients may benefit from improved vaccine formulations that could lead to better protection against diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with cancers or chronic infectious diseases who may benefit from enhanced vaccine responses.
Not a fit: Patients with acute infections or those who do not have a significant immune response issue may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that significantly enhance the immune response against cancers and infectious diseases.
How similar studies have performed: Other research has shown success with mRNA vaccine technology, particularly in the context of COVID-19, suggesting a promising avenue for this novel application.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KEDL, ROSS M — UNIVERSITY OF COLORADO DENVER
- Study coordinator: KEDL, ROSS M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers